Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proto

Showing results (521-530 of 595) with videos related to

Pageof 60
Sort By:
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeGiuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Nature Communications|February 10, 2026
An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse modelsJesus M Ontoria, Esther Torrente, Antonino Missineo, et al.
Clinical Lung Cancer|September 29, 2023
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver AlterationsMarta Brambilla, Teresa Beninato, Anna Piemontese, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Journal of Cardiothoracic and Vascular Anesthesia|September 20, 2023
One-Lung Ventilation and Postoperative Pulmonary Complications After Major Lung Resection Surgery. A Multicenter Randomized Controlled TrialFederico Piccioni, Nicola Langiano, Elena Bignami, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialMarco Platania, Felice Pasini, Luca Porcu, et al.
Pageof 60

Showing results (521-530 of 595) with videos related to

Sort By:
Pageof 60
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeGiuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Nature Communications|February 10, 2026
An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse modelsJesus M Ontoria, Esther Torrente, Antonino Missineo, et al.
Clinical Lung Cancer|September 29, 2023
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver AlterationsMarta Brambilla, Teresa Beninato, Anna Piemontese, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Journal of Cardiothoracic and Vascular Anesthesia|September 20, 2023
One-Lung Ventilation and Postoperative Pulmonary Complications After Major Lung Resection Surgery. A Multicenter Randomized Controlled TrialFederico Piccioni, Nicola Langiano, Elena Bignami, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialMarco Platania, Felice Pasini, Luca Porcu, et al.
Pageof 60